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A B S T R A C T
Objectives: To evaluate and compare clinical eﬃcacy of a 1.5% dipotassium oxalate monohydrate (KOX)-con-
taining oral rinse (‘Test’) for the relief of dentinal hypersensitivity (DH) against Negative Control and Placebo
oral rinses, adjunctive to twice-daily brushing with a standard ﬂuoride dentifrice, after 8 weeks.
Methods: This was a randomised, examiner blind, parallel-group, method development study in participants
with DH, assessed at baseline and after 4 and 8 weeks by response to an evaporative (air) stimulus (evaluated by
Schiﬀ sensitivity score and a 10-point visual rating scale [VRS]) and a tactile stimulus (Yeaple probe). To boost
compliance, study features included recruiting only regular oral rinse users, use of an oral rinse during accli-
matisation, weekly supervised rinsing and twice-daily text reminders.
Results: After 8 weeks, adjusted mean change from baseline in Schiﬀ sensitivity score was signiﬁcantly lower in
the Test rinse group (n = 43) versus the Negative Control group (n = 23) (diﬀerence: −1.22; 95% CI −1.657,
−0.782); tactile threshold score was signiﬁcantly higher in the Test rinse group compared to the Negative
Control rinse (diﬀerence: 37.46 g; 95% CI: 22.916, 51.995). Similar signiﬁcant diﬀerences in Schiﬀ/tactile scores
were also demonstrated after 4 weeks use, after 4 and 8 weeks use as assessed by VRS and as compared to the
Placebo rinse (n = 23) in all instances. Study products were generally well tolerated.
Conclusions: The Test rinse showed statistically signiﬁcant improvements in DH compared to the Negative
Control and Placebo rinses after 8 weeks twice daily use. Compliance with the rinsing regimen and study visits
was excellent.
Clinical signiﬁcance: Additional compliance features incorporated into this dentinal hypersensitivity study –
recruitment of regular oral rinse users only, acclimatisation rinse, weekly supervised rinsing at the study site,
twice-daily text reminders – appear to have been of beneﬁt to the overall study design as compliance was high,
and primary and secondary objectives were met.
1. Introduction
The short, sharp pain associated with dentinal hypersensitivity (DH)
occurs when exposed dentin tubules are stimulated by tactile, thermal
or chemical means, such as with hot food or cold air, causing movement
of ﬂuid within these tubules [1–3]. Management of DH can involve
home use oral care products that either desensitise the aﬀerent nerve,
blocking the pain response, or occlude the end of the dentin tubules,
blocking ﬂuid movement following stimulation [4]. Nerve desensitising
agents, such as potassium salts, generally take a number of days or
weeks to work, whereas tubule occluding agents (i.e., oxalates, bioglass,
strontium and stannous salts, or silicas) generally work more rapidly
[5–8].
A number of successful clinical studies have been conducted on oral
rinses containing the occluding agent dipotassium oxalate (KOX),
available as over-the-counter products [9–11]. Recently, three rando-
mised double-blind, placebo-controlled studies of a similar design were
conducted to evaluate the DH eﬃcacy of three diﬀerent 1.5–2.0% KOX-
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containing (as dipotassium oxalate monohydrate) oral rinses [12].
Statistically signiﬁcant improvements were found in favor of KOX oral
rinses versus a placebo rinse in one of these studies but not the other
two. The reason for the lack of statistical diﬀerentiation in these studies
was unclear as KOX had been shown to be eﬀective in reducing DH in
other published clinical studies [9–11].
The mixed results observed by Burnett et al [12] with KOX oral
rinses prompted an investigation by conducting this method develop-
ment clinical study. It has been demonstrated that long-term com-
pliance with dental hygiene instructions is low, at 37% in one follow-up
study [13] and 51% in another [14] and it can be hypothesized this may
also be the case during clinical studies. Today’s society uses mobile
phones as their primary mode of communication and there are over
four billion mobile phone subscribers worldwide [15]. Text messaging
is a fast, cheap and eﬃcient way for people to communicate via their
mobile phone. Multiple medical studies report signiﬁcant compliance
beneﬁts when utilising electronic technology to enhance interventions
for weight loss, drug adherence, physical activity, smoking cessation
and diabetes management, among others [16–19]. One dental study,
designed to evaluate oral hygiene improvement in orthodontic patients
who received weekly text messages, found greater reductions in plaque,
gingival inﬂammation and bleeding compared to those who did not
receive text message reminders [20].
The plan of this study was such that it was used to explore some of
the areas of clinical design in a DH study that could be used for ex-
amining eﬃcacy of existing and future DH oral rinse technologies. This
8 week method development study aimed to compare clinical eﬃcacy
of a 1.5% KOX-containing oral rinse developed for relief of DH com-
pared to a negative control oral rinse and a placebo rinse, all used
twice-daily alongside a standard ﬂuoride toothpaste. In this current
investigation, eﬀorts were made to ensure compliance in a number of
ways including recruiting only regular oral rinse users, using an oral
rinse during the acclimatisation period, supervising rinsing at the study
site and sending twice-daily phone text reminders to participants.
2. Materials and methods
This was a single center, 8 week, randomised, examiner-blind,
three-treatment, parallel-group, method development study with
healthy participants with a self-reported history of DH. The study was
conducted at a USA-based clinical research center and was approved by
an independent review board before initiation (U.S. Investigational
Review Board, Inc. Miami, FL, 33143 USA: U.S.IRB2017SRI/05). It was
carried out in accordance with the International Conference on
Harmonisation Guideline for Good Clinical Practice (E6) in agreement
with the Declaration of Helsinki. This study was registered at
Clinicaltrials.gov: NCT03238352. Anonymised individual participant
data and study documents can be requested for further research from
www.clinicalstudydatarequest.com.
2.1. Participants
The study enrolled healthy participants aged 18–65 years old who
were regular oral rinse users with a minimum of 20 natural teeth and a
self-reported history of DH lasting more than 6 months but not more
than 10 years. General exclusion criteria included pregnancy; breast-
feeding; hypersensitivity to study materials; a xerostomia-causing
condition or medication; kidney disease, hyperoxaluria or any condi-
tion that could be exacerbated by oxalic acid or oxalate salts; use of an
oral care product indicated for DH relief within 8 weeks of screening
and participation in a clinical study or receipt of an investigational drug
within 30 days of screening. General oral exclusions included: re-
quirement for antibiotic prophylaxis for dental procedures; tongue/lip
piercings; dental implants; dental prophylaxis within 4 weeks, de-
sensitizing treatment or tooth bleaching within 8 weeks, scaling or root
planing within 3 months and gross periodontal disease and/or
treatment of such within 12 months of screening. Speciﬁc dentition
exclusions for selected test teeth included evidence of current or recent
caries or treatment of decay within 12 months of screening; a sensitive
tooth not expected to respond to treatment or with contributing etiol-
ogies other than erosion, abrasion or facial/cervical gingival recession
(EAR); exposed dentin but with deep, defective or facial restorations
and teeth with full crowns or veneers, cracked enamel, orthodontic
bands or used as abutments for ﬁxed or removable partial dentures.
2.2. Study procedures
At the screening visit, written informed consent to participate in the
study was obtained, and demography, ethnicity, medical history, and
concomitant medications were recorded. The examiner performed
complete oral hard tissue and oral soft tissue (OST) examinations,
dentition exclusions, assessment of EAR, gingival status, using the
Modiﬁed Gingival Index [21], and tooth mobility, using a modiﬁcation
of the Miller scale [22]. A positive pain response was tested via a direct
1 second application of air from a standard dental syringe from a dis-
tance of around 1 cm.
Eligible study participants were supplied with a standard ﬂuoride
dentifrice (1000 ppm ﬂuoride as sodium monoﬂuorophosphate;
Colgate® Cavity Protection; Colgate-Palmolive Company, New York,
USA), a toothbrush (Oral-B® Sensi Soft Manual Toothbrush; Proctor &
Gamble, Cincinatti, OH USA) and a marketed ﬂuoride oral rinse (Crest®
Pro-Health Advanced with Extra Deep Clean mouthwash; Procter &
Gamble, Cincinnati, OH, USA) to use twice-daily (morning and evening)
during the 2–3 week acclimatisation period between screening and
baseline visits. These products were selected as the did not contain any
known anti-sensitivity ingredients. Additionally, the over-the-counter
monograph directions (twice daily) and quantity of use (10 ml) for both
rinses were aligned with the directions and quantity of use of the test
KOX oral rinse Each product use was recorded in a provided diary. First
use of the acclimatisation dentifrice and oral rinse was carried out
under study site supervision.
At the baseline visit (2–3 weeks after screening), eligibility to con-
tinue was conﬁrmed with a review of the inclusion/exclusion criteria.
Participants underwent an OST examination, followed by tooth sensi-
tivity assessments: a tactile stimulus evaluation using a Yeaple probe
[23] with maximum 20 g pressure, then, at least 5 minutes after the
tactile assessment, an evaporative (air) stimulus with participant reac-
tion recorded using the Schiﬀ Sensitivity Scale [24] (See ‘Assessments’
section for details). From the results of these, two non-adjacent test
teeth were selected that had a tactile threshold ≤20 g and a Schiﬀ
sensitivity score ≥2.
Eligible participants were stratiﬁed according to the maximum
baseline Schiﬀ sensitivity score (2 or 3) of the two selected test teeth
then assigned to a study group in accordance with a randomisation
schedule generated by an independent statistics agency prior to the
start of the study, using validated software (SAS version 9.4; SAS
Institute Inc., Cary, NC, USA). Randomisation numbers within each
stratum were assigned in ascending numerical order according to ap-
pearance time for the baseline visit.
Participants were randomised into one of the following groups using
a stratiﬁed randomised block design with a 2:1:1 ratio:
• Test rinse: Experimental oral rinse containing 1.5% w/w KOX and
0 ppm ﬂuoride;
• Negative Control rinse: Commercially available oral rinse containing
0.02% w/w sodium ﬂuoride (Colgate® Total Daily Repair; Colgate-
Palmolive Company);
• Placebo rinse: Oral rinse containing 0% w/w KOX and 0 ppm
ﬂuoride.
Participants ﬁrst carried out their allocated study regimen under
supervision at the study site. They were instructed to brush for 1 timed
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minute in their usual manner with the standard ﬂuoride toothpaste
(Colgate® Cavity Protection) and expectorated. They then rinsed with
10 mL of tap water for 5 seconds and expectorated; then rinsed with
10 mL of their assigned oral rinse for 60 timed seconds and ex-
pectorated. No further rinsing with water was permitted after oral rinse
use; participants were asked to refrain from eating or drinking for 30
minutes. Participants continued to use their assigned study treatment
twice-daily (morning and evening) for the next 8 weeks, recording each
brushing and rinsing occasion in the diary provided.
The examiner, study statistician and any other sponsor employees
who could inﬂuence study outcomes were blinded to the treatment
received. Dispensing staﬀ were not involved in any eﬃcacy assess-
ments. While participants’ group allocation was not disclosed to them,
due to diﬀerences in product taste, appearance and packaging (though
products were dispensed without commercial labels), participants could
not be fully deemed ‘blinded.’
All study participants were sent twice-daily (morning and evening)
text message reminders requesting them to perform their timed brush
and rinse. Participants returned to the study site once each week over
the 8 week study period bringing their study kit so that the oral rinse
bottle and its contents could be weighed to verify study compliance.
Diaries were checked to assess compliance and participants undertook a
supervised brushing and rinse.
2.3. Assessments
The assessment of DH using two diﬀerent stimuli follows the re-
commendation of Holland et al [6]. Tooth sensitivity was assessed at
baseline and then after 4 and 8 weeks of treatment, using ﬁrst a tactile
stimulus (Yeaple probe), then an evaporative (air) stimulus (with Schiﬀ
Sensitivity Scale and VRS) on the two selected test teeth only. An OST
examination was completed at each of these visits prior to clinical as-
sessments of sensitivity.
Tactile assessments were performed by a single trained examiner
using a constant-force (Yeaple) probe. At baseline, a maximum 20 g
force was applied; at subsequent visits it was 80 g. Testing began at 10 g
and increased by 10 g with each successive challenge until a “yes” re-
sponse for a painful stimulus was recorded. The force setting which
elicited the “yes” response was repeated. If a second “yes” was not
obtained, the force setting would be increased by 10 g and continued
until a force was found to elicit two consecutive “yes” responses. If no
pain response was found, the threshold was recorded as> 80 g.
The evaporative (air) stimulus followed the tactile assessment after
at least 5 minutes to allow recovery time. The examiner’s assessment of
the participant’s response to the air stimulus was recorded on the four-
point Schiﬀ Sensitivity Scale where: 0 = participant does not respond
to air stimulus; 1 = participant responds to air stimulus but does not
request discontinuation; 2 = participant responds to air stimulus and
requests discontinuation or moves from stimulus; 3 = participant re-
sponds to stimulus, considers stimulus to be painful and requests dis-
continuation of the stimulus [24]. Participants also rated the intensity
of their response to the evaporative (air) stimulus using a 10-point vi-
sual rating scale (VRS) to mark their pain on a scale of 1 (‘no pain’) to
10 (‘intense pain’).
2.4. Safety
A trained dental evaluator performed intraoral examinations at each
study visit. All adverse events (AEs) were recorded and monitored
throughout the study. The AEs and any observed abnormalities noted
during the OST examination were transcribed from the screening visit
until 5 days after ﬁnal use of study product. The investigator de-
termined the causal relationship of each AE using their clinical ex-
perience and classed severity as mild, moderate, or severe. Treatment-
emergent adverse events (TEAEs) were reported for the safety popula-
tion, which included all randomised participants who received study
product.
2.5. Data analysis
A suﬃcient number of people were to be screened in order to ran-
domize at least 100 participants (approximately 50 to the Test rinse, 25
to the Negative Control rinse, 25 to the Placebo rinse groups) to ensure
80 evaluable participants completed the entire study. With this 2:1:1
distribution of participants in the treatment arms the study had less
than 50% power to detect a mean treatment diﬀerence of 0.36 in the
Schiﬀ sensitivity score using a 2-sided t-test of signiﬁcance level 0.05
for the Test rinse against the Negative Control rinse. The standard de-
viation (SD) used in this calculation was 0.8; this estimate was obtained
from a previous study [12]. The Test rinse group was also compared
with a combined group comprised of the Negative Control and Placebo
rinse groups using the 2-sided t-test with the same estimates of mean
diﬀerence, signiﬁcance level and SD. In this instance, the study had
51.1% power. All statistical analyses were conducted using SAS 9.4.
Analysis was carried out on a modiﬁed intent-to-treat (mITT) po-
pulation, deﬁned as all randomised participants who received at least
one dose of study treatment and had at least one post-baseline eﬃcacy
evaluation. The per protocol (PP) population included all participants
in the mITT population who had no protocol deviations deemed to af-
fect eﬃcacy.
The primary analysis was a comparison of mean change from
baseline in Schiﬀ sensitivity score between the Test rinse and Negative
Control rinse regimens at Week 8. Analysis of Covariance (ANCOVA)
was used to determine the change from baseline in Schiﬀ sensitivity
score at Weeks 4 and 8 with treatment as a factor and mean baseline
Schiﬀ sensitivity score as a covariate. Change from baseline in the
tactile threshold at Weeks 4 and 8 was analysed using an ANCOVA with
treatment and baseline Schiﬀ stratiﬁcation as factors and baseline tac-
tile threshold as a covariate. Analysis was conducted for the Test rinse
versus the Negative Control rinse or the Placebo rinse and also versus a
combined group of the Negative Control rinse and Placebo rinse.
The assumption of normality and homogeneity of variance in the
ANCOVA model was investigated and, if violated, data transformations
were to be investigated. If suitable transformations could not be found,
non-parametric Van Elteren tests were to be performed, adjusting for
the maximum baseline Schiﬀ sensitivity scores, and results were com-
pared with the ANCOVA results. If the inferences from the two analyses
were similar, then both sets of results were to be reported with em-
phasis on the ANCOVA results. In case of discrepancies between p-va-
lues of ANCOVA and Van Elteren analysis, inferences were drawn on
the non-parametric analysis.
3. Results
A total of 123 participants were screened for entry into the study; 89
participants were randomised (Safety Population) and 85 (95.5%)
completed the study (Fig. 1). Overall, most participants were female
(88.8%) and were of White/Caucasian/European Heritage (84.3%). The
demographic characteristics were similar among participants in each
group (Table 1). The ﬁrst participant entered the study on August 7th,
2017, the last participant ﬁnished the study on October 27th, 2017.
For one participant in the Negative Control rinse group and one in
the Placebo rinse group, product non-compliance was frequent and
outside the 80–120% window. These two participants were excluded
from the PP population; however, as it was pre-speciﬁed that the PP
population was only to be analyzed if more than 10% of the mITT
population were excluded, and this was not the case, only the mITT
population was analysed.
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4. Eﬃcacy
4.1. Schiﬀ sensitivity score
After 8 weeks of treatment, the adjusted mean change from baseline
in Schiﬀ sensitivity score showed a greater improvement in the Test
rinse group than in the Negative Control rinse group [-1.94; 95% con-
ﬁdence interval (CI):−2.188,−1.697 versus−0.72; 95% CI:−1.085;
−0.361, respectively] (Fig. 2). The diﬀerence between the adjusted
mean scores for the Test rinse and Negative Control rinse groups was
−1.22 (95% CI: −1.657, −0.782) and was statistically signiﬁcant
(p < 0.0001) in favor of the Test rinse. The Test rinse was also sta-
tistically signiﬁcantly diﬀerent from both the Negative Control rinse at
4 weeks, and from the Placebo rinse and combined control groups at 4
and 8 weeks (p < 0.0001 for all except Test versus Placebo at 4 weeks
where p = 0.0004) (Table 2).
4.2. Tactile threshold
After 8 weeks of treatment, the adjusted mean change from baseline
in tactile threshold was higher for the Test rinse group than the
Negative Control rinse group (61.31 g; 95% CI: 53.120, 69.503 versus
23.86 g; 95% CI: 11.848, 35.863, respectively) (Fig. 3). The diﬀerence
between the adjusted mean scores for the Test rinse and Negative
Control rinse groups was 37.46 g (95% CI: 22.916, 51.995) and was
statistically signiﬁcant (p < 0.0001) in favor of the Test rinse. The Test
rinse was also statistically signiﬁcantly diﬀerent from both the Negative
Control rinse at 4 weeks, and the Placebo rinse and combined control
groups at 4 and 8 weeks (p < 0.0001). Assumptions of normality and
homogeneity of residuals were investigated; minor departures were
observed. Supportive non-parametric results from the Van Elteren test
were similarly statistically signiﬁcant at all time points and for all
comparisons (p < 0.0001 for all except Test rinse versus Negative
Control rinse at 8 w where p = 0.0004) (Table 2).
4.3. Visual rating scale
All VRS scores decreased from baseline (Fig. 4) with most being
statistically signiﬁcantly diﬀerent at both 4 and 8 weeks in favor of the
Test rinse group versus the Negative Control rinse, the Placebo rinse
and the combined control groups (p < 0.005). The exception was a
non-signiﬁcant diﬀerence (p = 0.069) between the Test rinse versus
the Placebo rinse at 4 w (Table 2).
5. Safety
Overall, six participants (6.7%) experienced six TEAEs (Table 3). All
TEAEs were mild/moderate in intensity and had resolved by study
completion. Two participants (2.2%) reported two TEAEs that were
considered treatment-related: one report of mild oral discomfort in the
Test rinse group; one report of mild oral mucosal exfoliation in the
Placebo rinse group. There were no deaths, no serious AEs, no medical
devise incidents, and no participants with AEs that led to discontinua-
tion of treatment or withdrawal from the study.
6. Discussion
In this study, signiﬁcant improvements in DH were demonstrated
when using an experimental 1.5% w/w KOX-containing oral rinse for 8
weeks compared to using Negative Control and Placebo rinses when
each was used as an adjunct to twice-daily brushing with a standard
ﬂuoride toothpaste. It is believed that participant perception scales such
as VRS can sometimes be less reliable for measuring DH than examiner
derived scores such as Schiﬀ Sensitivity Scale, as responders tend to
concentrate scores in one area of the scale [25]. However, in this study
the trends observed for VRS were aligned with those for the Schiﬀ
Sensitivity Scale and tactile threshold scores, with the greatest reduc-
tion in DH being consistently observed for the Test rinse group.
KOX was selected as the Test oral rinse as this oxalate-based oc-
cluding agent has been shown to be eﬀective in reducing DH [9–11]. In
a previous series of three studies, the experimental 1.5% w/w KOX-
containing oral rinse showed statistically signiﬁcant DH eﬃcacy com-
pared to a placebo oral rinse in one study, but no signiﬁcant diﬀerences
were found in the other two [12]. To optimise the study design and help
to ensure compliance, the current method development study included
a number of new features that were not considered in the earlier oral
rinse studies. For instance, only regular (twice-daily) oral rinse users
were recruited such that the rinsing habit had already been established
and the rinse instructions would be similar to their normal oral hygiene
practice. This study also included an oral rinse during the acclimati-
sation period, whereas in Burnett et al [12] only a toothpaste was used
at this stage. This was introduced to minimise potential placebo/
Fig. 1. Study Flow.
mITT: modiﬁed intent-to-treat; pop: population.
Table 1
Demographic characteristics (safety population).
Test rinse (N = 43) Negative Control (N = 23) Placebo (N = 23)
Sex, n (%) Male 6 (14.0) 4 (17.4) 0
Female 37 (86.0) 19 (82.6) 23 (100)
Race, n (%) African American/African heritage 6 (14.0) 2 (8.7) 3 (13.0)
White/Caucasian/European/Arabic heritage 37 (86.0) 20 (86.9) 20 (87.0)
American/Alaskan native 0 1 (4.3) 0
Age Mean (SD) 46.0 (9.27) 41.5 (9.76) 43.0 (8.75)
Range 24–61 24–58 28–58
Stratiﬁcationa Schiﬀ score 2 9 (20.9) 5 (21.7) 5 (21.7)
Schiﬀ score 3 34 (79.1) 18 (78.3) 18 (78.3)
n(%) = number (percent) of participants; SD = standard deviation.
a Maximum baseline Schiﬀ score.
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Hawthorne eﬀects and to standardise participants’ oral care regimen,
given that there would be no change in regimen moving from the ac-
climatisation period to the test period.
As a number of studies have found that the use of text message
reminders can enhance study compliance [16–20], here, twice-daily
text message reminders were sent to participants. They also undertook a
weekly supervised brushing and rinsing at the study site, during which
they were asked to measure out the 10 ml dose of oral rinse to conﬁrm
and correct any deviations from the regimen instructions. Participants
were also asked to bring their assigned oral rinse bottles at each visit so
that the contents could be weighed and compliance assessments could
be conﬁrmed. As a result of these changes, compliance was extremely
high and only two participants were deemed non-compliant with the
brushing/rinsing regimen.
One limitation of this study is that there were several exclusions in
terms of the selected study population. As this was a method develop-
ment study, the population needed to be controlled in such a way that
enabled the eﬀect of the added compliance features to be observed.
Further studies may require less stringent exclusions to be able to ex-
trapolate data to the general population.
In conclusion, additional compliance features incorporated into this
DH study – including recruiting only regular oral rinse users, addition
of using an oral rinse during the acclimatisation period, weekly
supervised rinsing at the study site and twice-daily text reminders –
appear to have been of beneﬁt to the overall study design as compliance
was high and all primary and secondary objectives were met. The
ﬁndings of this study add weight to other studies showing the utility of
a 1.5% w/w KOX-containing oral rinse in lowering symptoms of DH.
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Table 2
Statistical analysis of change from baseline in evaporative (air) Schiﬀ sensitivity, tactile threshold and VRS scores (mITT Population).
Treatment comparison Diﬀerence (standard error)a
[95% CI] p-value
Schiﬀ sensitivity score Tactile threshold score VRS score
Week 4 Test rinse vs Negative Control −0.87 (0.201)
[−1.273, −0.473] <0.0001
29.96 (7.035)
[15.963, 43.962] < 0.0001c
−1.35 (0.456)
[−2.256, −0.440] 0.0041
Test rinse vs Placebo −0.72 (0.194)
[−0.107, −0.334] 0.0004
28.66 (6.816)
[15.094, 42.224] < 0.0001c
−0.82 (0.445)
[−1.705, 0.067] 0.0695
Test rinse vs Combined Control −0.80 (0.161)
[−1.116, −0.477] <0.0001
29.31 (5.645)
[18.077, 40.544] < 0.0001c
−1.08 (0.368)
[−1.815, −0.352] 0.0042
Week 8 Test rinse vs Negative Control −1.22 (0.220)b
[−1.657, −0.782] <0.0001
37.46 (7.306)
[22.916, 51.995] < 0.0001d
−2.06 (0.527)
[−3.108, −1.010] 0.0002
Test rinse vs Placebo −1.28 (0.213)
[−1.705, −0.858] <0.0001
49.88 (7.079)
[35.791, 63.966] < 0.0001c
−1.72 (0.514)
[−2.742, −0.695] 0.0013
Test rinse vs Combined Control −1.25 (0.176)
[−1.600, −0.901] <0.0001
43.67 (5.862)
[32.001, 55.334] < 0.0001c
−1.89 (0.425)
[−2.734, −1.044] < 0.0001
a Diﬀerence is ﬁrst named treatment minus second named treatment such that a negative (Schiﬀ sensitivity score, VRS score) or positive (tactile threshold score)
diﬀerence favours ﬁrst named treatment.
b Primary comparison.
c Supportive non-parametric analysis p < 0.0001.
d Supportive non-parametric analysis p = 0.0004.
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